Finally, baseline levels of CXCL13 were unaltered between patients with different tumor localizations, TNM stages, tumor grading, resection status or sex but were significantly higher in patients with an impaired ECOG performance status (Figure S3A–H). The gene discussed is CXCL13; the disease is neoplasm.